

CDK4/6 Inhibitoren

Univ.-Prof. Dr. Christian F Singer, MPH

Leiter, Brustgesundheitszentrum Wien

Medizinische Universität Wien

Adjuvant Endocrine Therapy 1962 -



Tamoxifen (1962-)



Aromatase Inhibitors (1987-)



Adjuvant Endocrine Therapy 1962 -



Tamoxifen (1962-)



Aromatase Inhibitors (1987-)

+



CDK4/6i (2016-)




CDK4/6 Inhibitoren

NATALEE (Ribociclib): 5-Jahresdaten

Survival Status Over Time: Fewer BC-Related Deaths in RIB Arm

A positive OS signal in favor of RIB + NSAI treatment has been observed at earlier timepoints



BC, breast cancer; HR, hazard ratio; iDFS, invasive disease-free survival; ITT, intention to treat; NSAI, nonsteroidal aromatase inhibitor; RIB, ribociclib; OS, overall survival.



John Crown, M.D.

Content of this presentation is copyright and responsibility of the author. Permission is required for re-use.



CDK4/6 Inhibitoren

Monarch E (Abemaciclib): Überlebensvorteil



CDK4/6 Inhibitoren

Kürzere Serviceintervalle...



Complete blood counts, liver function tests, an ECG and electrolyte monitoring should be performed before initiating treatment with KISQALI.

Any additional monitoring should be performed as per the SmPC and as clinically indicated.¹

The recommended monitoring schedule can be found opposite.

		CYCLE 1 (28 DAYS)	CYCLE 2 (28 DAYS)	CYCLE 3 (28 DAYS)	CYCLE 4 (28 DAYS)	CYCLE 5 (28 DAYS)	CYCLE 6 (28 DAYS)
BLOOD TEST 	CBC LFT*	Baseline [§] and mid-cycle	Beginning and mid-cycle	Beginning of each cycle			
	Electrolytes †	Baseline [§]	Beginning of each cycle				
3 ECGs 	QTcF‡	Baseline* and mid-cycle (approximately Day 14)	Beginning	AS CLINICALLY INDICATED			

MONITORING AS CLINICALLY INDICATED BEYOND CYCLE 6

CDK4/6 Inhibitoren

Der Preis: Überlastung der Infrastruktur...



Alt: 12 Termine in 3 Jahren

Neu: 18 - 36 Termine in 3 Jahren